Advanced Basal Cell Carcinoma: Navigating an Evolving Therapeutic Landscape: A Care Team ForumSM

Program Overview

Therapeutic options for advanced basal cell carcinoma (BCC) have been transformed by the introduction of Hedgehog pathway inhibitors (HPIs) and the emergence of immunotherapy. Led by a multidisciplinary expert panel, this activity uniquely features an experienced patient sharing key insights from their treatment journey. The discussion focuses on the role and place of HPIs and PD-1 inhibitors in advanced BCC and provides professional guidance on managing class-specific toxicities, including immune-mediated adverse events.

Credit Expired
0.75 CE Credit(s)
Expires: April 8, 2022

Target Audience

This activity is designed to meet the educational needs of dermatology and oncology physicians who diagnose and manage patients with advanced basal cell carcinoma (BCC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Apply current data to the appropriate selection of Hedgehog inhibitors in advanced basal cell carcinoma (BCC)
  • Evaluate the role and place of immunotherapy in managing patients with advanced BCC

Activity Faculty

Hamid, Omid

Omid Hamid, MD

Chief, Translational Research and Immunotherapy
Director, Melanoma Center and Phase I Immuno-Oncology Program
The Angeles Clinic and Research Institute
Los Angeles, CA
M. Lacotour Headshot

Mario Lacouture, MD

Director, Oncodermatology Program
Professor of Dermatology
Memorial Sloan Kettering Cancer Center
New York City, NY

Michelle Offner Headshot

Michelle Offner, RN, MSN, ACNP-BC

Nurse Practitioner, Medical Oncology (Cutaneous Malignancies)
The Angeles Clinic and Research Institute
Los Angeles, CA

Supporter Statement

Provider Statement

Disclosure of Financial Relationships

Faculty

Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources